

NHMRC FUNDING COMMENCING IN 2012 FOR AMREP

Details of grants awarded to AMREP chief investigators (CI-A) commencing in 2012 are listed below. The names of AMREP staff members are in bold type.

NHMRC

Program Grants (funding commencing in 2013)

- **Kaye D, Jennings G, Esler M, Dart AM, Kingwell B, Chin-Dusting J, Sviridov D.** A program of translational cardiovascular medicine: identifying new targets for prevention and treatment \$12,406,615 **Baker IDI**

Centres of Research Excellence (funding commencing in 2011)

- **Cameron P.** Australian Resuscitation Outcomes Consortium \$2,498,523 **Monash**

Partnership Projects (funding commencing in 2011)

- **Lewin S.** HealthMap: a cluster randomised trial of interactive self-care plans to prevent and manage chronic conditions by people living with HIV \$1,497,150 **Monash**

NHMRC-European Union Collaborative Research Grants

- **Jowett J.** Identification of epigenetic markers underlying increased risk of T2D in South Asians \$218,078 **Baker IDI**

Project Grants

- **Allen T, Chai Z.** Modulation of TGF-beta signaling by CDA1 in the diabetic vasculature \$506,250 **Baker IDI**
- **Allen T, Cooper M.** Angiotensin II AT2 receptor in diabetic atherosclerosis \$488,322 **Baker IDI**
- **Bellomo R.** The Australasian Resuscitation in Sepsis Evaluation – Randomised Controlled Trial – continuation funding request \$349,790 **Monash**
- **Bobik A, Toh BH, Tipping P.** CD4 NKT cells and atherosclerosis: molecular mechanisms and therapeutic strategies for suppression \$487,260 **Baker IDI**
- **Bozaoglu K.** Chemerin may be a novel therapeutic target for modulation of adipose tissue mass \$516,325 **Baker IDI**
- **Bruce C, Lee-Young R.** Sphingosine kinase: a target for obesity-induced insulin resistance \$533,675 **Baker IDI**
- **Carey A.** Adrenergic activation of brown adipose tissue in humans \$314,950 **Baker IDI**
- **Cooper DJ.** STandaRd Issue TrANsfusion versus Fresher red blood cell Use in intenSive carE (TRANSFUSE): a randomised controlled trial \$2,761,870 **Monash**
- **Cooper M, El-Osta A, Jandeleit-Dahm K.** Role of Set7 in diabetes related end-organ injury \$864,770 **Baker IDI**
- **Degenhardt L.** Pharmaceutical opioid prescription for chronic pain in Australia: trajectories of prescribing, risk of adverse events, and predictors of harm \$1,041,601 **Burnet**
- **Drummer H.** Roles of the hepatitis C virus glycoprotein E2 variable regions in virus entry, immunogenicity and immune evasion \$659,685 **Burnet**

NHMRC FUNDING COMMENCING IN 2012 FOR AMREP

- **El-Osta A, Du XJ.** Regulating gene expression changes in cardiac hypertrophy \$667,350 **Baker IDI**
- **Fisher J.** A brief couple-focused psychoeducational intervention to prevent postnatal mental health problems in women: a cluster randomised trial \$679,499 **Monash**
- **Gabbe B.** Improving the measurement of non-fatal injury burden – validating the Global Burden of Disease (GBD) project through synthesis and analysis of the six leading injury outcome cohort studies from around the world \$151,755 **Monash**
- **Glass D.** Immunological and respiratory effects among workers exposed to engineered nanoparticles \$499,222 **Monash**
- **Gerondakis S.** The NF- κ B transcription factors c-Rel and RelA control multiple steps in natural CD4 regulatory T cell development \$548,005 **Burnet**
- **Gorry P.** Elucidating unique molecular mechanisms involved in HIV-1 subtype C pathogenicity \$686,365 **Burnet**
- **Guthridge M.** Dual inhibition of independent cell survival pathways as a new approach for targeting leukemic stem cells \$543,675 **Monash**
- **Hagemeyer C, Johnston A, Peter K.** Antibody targeted thrombin-activatable μ -plasminogen fusion proteins and nanocapsules for the treatment of acute thrombosis \$518,675 **Baker IDI**
- **Jackson S.** Investigation of a new leukocyte recruitment mechanism at sites of vascular injury \$528,675 **Monash**
- **Jane S.** A novel genetic element controlling adult haemoglobin production \$477,260 **Monash**
- **Jane S.** Identification of critical factors for the establishment and maintenance of the epidermal barrier \$648,675 **Monash**
- **Jowett J, Blangero J.** Genetics to function: identifying transcripts mediating the biological effects of GWAS SNPs \$423,579 **Baker IDI**
- **Jowett J, Blangero J, Nyholt D.** Exome sequencing by NGS to identify rare variants affecting Type 2 diabetes \$553,510 **Baker IDI**
- **Lewin S.** Liver disease in HIV-HBV co-infection \$682,330 **Monash**
- **Lambert G, Barton D.** Interactions between the serotonin transporter and sympathetic nervous activation in patients with major depressive disorder - Understanding the link between the brain and the heart \$509,250 **Baker IDI**
- **Lambert G, Barton D, Dixon J, Straznicki N.** A randomised trial examining the effectiveness of sympathetic nervous inhibition in alleviating the metabolic side effects of antipsychotic medications in patients with schizophrenia \$461,250 **Baker IDI**
- **Lambert G, Teede H, Dixon J, Tilbrook A.** Polycystic ovary syndrome - targeting the sympathetic nervous system to improve outcomes \$341,175 **Baker IDI**
- **Magliano D, Shaw Jo, Peeters A, Kookana R, Melzer D, Mueller J.** The role of Bisphenol A in the development of chronic disease \$384,002 **Baker IDI**

NHMRC FUNDING COMMENCING IN 2012 FOR AMREP

- **Meikle P**, Tonkin A, **Jowett J**, Kowalczyk A, Hillis G, Zoungas S, Thompson P. Metabolomic insights into the pathogenesis and risk assessment of unstable coronary artery disease \$847,185 **Baker IDI**
- **Nichol A**. A multi-centre RCT of an open lung strategy including permissive hypercapnia, alveolar recruitment and low airway pressure in patients with ARDS \$997,535 **Monash**
- **O’Hehir R**. Impaired respiratory tolerance in obesity – the link with asthma? \$644,685 **Monash**
- **Oldenburg B**. A prospective cohort study investigating the relationships between negative emotions, biomarkers and long term functioning in post-MI patients \$851,071 **Monash**
- **Peeters A**. Predicting the impact of current obesity and diabetes trends on future prevalence of cardiovascular disease in Australia \$217,430 **Monash**
- **Peter K, Hagemeyer C**, Ackermann U, O’Keefe G. Novel 18F and 64Cu labelled targeted nanoparticles for molecular positron emission tomography: A means for early and sensitive detection of thrombosis, inflammation and vulnerable, rupture-prone atherosclerotic plaques \$553,510 **Baker IDI**
- **Ponsford J**. Efficacy of melatonin for sleep disturbance following traumatic brain injury \$217,407 **Monash**
- **Porello E**. Regulation of mammalian heart regeneration by the miR-15 family \$421,175 **Baker IDI**
- **Schlaich M, Lambert G**. Renal denervation for uncontrolled hypertension \$2,073,675 **Baker IDI**
- **Schoenwaelder S**. Investigating the contribution of distinct mitochondrial cell death pathways to platelet survival and function \$613,375 **Monash**
- **Stoové M**. A prospective cohort study of ex-prisoners with a history of injecting drug use: examining health service utilisation, physical and mental health and blood borne virus trajectories \$956,019 **Burnet**
- **Storey E**. The SNORE-ASA study: a study of neurocognitive outcomes, radiological and retinal effects of aspirin in sleep apnoea \$850,000 **Monash**
- **Sviridov D**, Bukrinsky M, Slobedman B, Mukhamedova N. ABCA1 – an intersection between infection, atherosclerosis and metabolic disorders \$631,671 **Baker IDI**
- **Sviridov D**, Smyth I, Jowett J, Fu Y, Kelsell D. ABCA12 – a new regulator of cellular lipid metabolism \$699,685 **Baker IDI**
- **Tachedjian G**. Lactic acid as a natural microbicide for HIV \$577,350 **Burnet**
- **Taylor A**. The role of diffuse myocardial fibrosis in myocardial stiffness \$479,940 **Baker IDI**
- **Teede H**. Preventing weight gain in young to mid-aged women living in rural communities: a cluster randomised controlled trial \$863,888 **Monash**
- **Thomas M, Tikellis C**. Exploring the therapeutic potential of TRAIL in diabetes and the metabolic syndrome \$431,250. **Baker IDI**

NHMRC FUNDING COMMENCING IN 2012 FOR AMREP

- **Urquhart D.** Is low dose amitriptyline more effective than placebo in the management of chronic, neuropathic low back pain? A double-blind, randomised, placebo-controlled trial with an economic evaluation \$296,155 **Monash**
- **Wright M.** The role of the tetraspanins CD37 and CD82 in leukocyte migration \$358,510 **Monash**
- **Woodcock E, Iismaa S.** Identification of novel targets for treatment of heart failure \$470,286 **Baker IDI**

Development Grants

- **Febbraio M, Cowley M, Adams T.** Development of a modified gp130 ligand to treat obesity-induced insulin resistance \$424,363 **Baker IDI**
- **Hagemeyer C.** Site-specific bioconjugation to improve antibody drug conjugate production \$391,805 **Baker IDI**
- **Meikle P, Kingwell B, Dart AM, Pekarsky B.** Plasma lipid profiling for risk assessment of unstable coronary artery disease \$499,750 **Baker IDI**

Research Fellowships

- **Clifton P.** PRF (2012-2016) **Baker IDI**
- **Febbraio M.** SPRF (2012-2016) **Baker IDI**
- **Mackay F.** SRF-B (2012-2016) **Monash**

Practitioner Fellowships

- **Gruen R.** PF1 (2012-2016) **Monash**
- **Kistler P.** PF1 (2012-2016) **Baker IDI**
- **Krum H.** PF1 (2012-2016) **Monash**

Career Development Fellowships

- **Carrington M.** Level 1 Population Health (2012-2015) **Baker IDI**
- **Kistler P.** Level 2 Clinical (2012-2015) **Baker IDI**

Early Career Fellowships

- **Binger K.** (2012-2015) **Baker IDI**
- **Elliott J.** (2012-2015) **Monash**
- **Hodgson C.** (2012-2015) **Monash**
- **Hodgson C.** (2012-2015) **Monash**
- **Panjari M.** (2012-2015) **Monash**

NHMRC FUNDING COMMENCING IN 2012 FOR AMREP

- **Richards J.** (2012-2015) *Burnet*
- **Ta H.** (2012-2015) *Baker IDI*
- **Weller C.** (2012-2015) *Monash*

Postgraduate Scholarships

- **Gibney K.** (2012-2014) *Monash*
- **Hopper I.** (2012-2014) *Monash*
- **Pearce H.** (2012-2014) *Baker IDI*